Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
257 hedge funds and large institutions have $1.52B invested in Catalyst Pharmaceutical in 2022 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 97 increasing their positions, 79 reducing their positions, and 22 closing their positions.
248% more call options, than puts
Call options by funds: $6.89M | Put options by funds: $1.98M
136% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 22
39% more capital invested
Capital invested by funds: $1.09B → $1.52B (+$428M)
23% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 79
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
12% more funds holding
Funds holding: 229 → 257 (+28)
1.95% less ownership
Funds ownership: 82.81% → 80.85% (-2%)
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$15.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.4M |
| 3 |
Millennium Management
New York
|
+$13.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.69M |
| 5 |
JAM
JW Asset Management
Miami Beach,
Florida
|
+$8.67M |
Top Sellers
| 1 |
LSV Asset Management
Chicago,
Illinois
|
-$36.6M |
| 2 |
Renaissance Technologies
New York
|
-$15.3M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$13.3M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$10.4M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$8.89M |
CPRX Hedge Fund Activity: Q4 2022 in Review
257 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2022, worth a combined $1.52B — up 39% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new CPRX positions and 22 closed out — a net gain of 30 holders — while 97 added to existing stakes and 79 trimmed.
The largest buyer was Deerfield Management, adding an estimated $15.2M. The largest seller was LSV Asset Management, cutting an estimated $36.6M.
- 257 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2022, up from 229 in Q3 2022.
- Funds reported $1.52B of Catalyst Pharmaceutical stock for Q4 2022, up 39% quarter-over-quarter.
- 52 funds opened new Catalyst Pharmaceutical positions in Q4 2022 and 22 closed out, a net change of +30 holders.
- The largest Catalyst Pharmaceutical buyer in Q4 2022 was Deerfield Management, an estimated $15.2M added.
- The largest Catalyst Pharmaceutical seller in Q4 2022 was LSV Asset Management, an estimated $36.6M sold.
Based on aggregated 13F filings for Q4 2022.